FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds—selective androgen receptor destructors (SARD), represented by structure of formulas I and VII. In formula, I T is OH; Z is CN; Y is CF3; R1 is CH3; R2 is hydrogen, C1-C12-alkyl; Q1, Q4 and Q5 are each independently selected from hydrogen, CN; Q2 and Q3 each represent hydrogen or phenyl substituted with halogen; where at least two Q1, Q2, Q3, Q4 and Q5 are not hydrogen; or Q2 and Q3 are bonded together to form unsubstituted C5-C8-carboxyclic ring. In formula VII, T denotes OH; Z is CN; Y is CF3; R1 is CH3 and Q1 is F, Cl, Br, I. Invention also refers to specific compounds of said formulas and a pharmaceutical composition containing them.
(I)
(VII).
EFFECT: selective androgen receptor destructive ligands (SARD) and methods for use thereof are disclosed.
15 cl, 8 tbl, 12 ex, 12 dwg
Title | Year | Author | Number |
---|---|---|---|
SELECTIVE ANDROGEN RECEPTOR DESTROYING (SARD) LIGANDS AND METHODS OF USING THEM | 2016 |
|
RU2689988C2 |
ANDROGEN RECEPTOR SELECTIVE DESTROYING (SARD) LIGANDS AND METHODS OF THEIR USE | 2017 |
|
RU2795431C2 |
THERAPEUTIC AGENTS BASED ON DIGLYCYLYL ETHER DERIVATIVES AND METHODS FOR USING THEM | 2009 |
|
RU2572596C2 |
OESTROGEN RECEPTOR LIGANDS AND METHODS OF USING THEM | 2010 |
|
RU2543339C2 |
BISPHENOL DERIVATIVES AND THEIR USE AS ACTIVITY MODULATORS OF ANDROGEN RECEPTOR | 2017 |
|
RU2767257C2 |
COMPOUNDS FOR TREATMENT OF CANCER | 2015 |
|
RU2805949C2 |
COMPOUNDS FOR TREATING CANCER | 2015 |
|
RU2733393C2 |
COMBINATION FOR TREATING PROSTATE CANCER, A PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATING | 2017 |
|
RU2733950C1 |
METHOD OF SYNTHESYSING DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | 2011 |
|
RU2554081C2 |
ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
Authors
Dates
2020-06-22—Published
2016-04-21—Filed